Ken Griffin Cabaletta Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.94 - $8.24 $17,336 - $36,256	-4,400 Reduced 23.28%	14,500 $68,000
Q2 2024 Aug 14, 2024	SELL	$7.22 - $18.82 $397,822 - $1.04 Million	-55,100 Reduced 74.46%	18,900 $141,000
Q1 2024 May 15, 2024	BUY	$16.79 - $25.38 $322,368 - $487,296	19,200 Added 35.04%	74,000 $1.26 Million
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $556,776 - $1.07 Million	45,600 Added 495.65%	54,800 $1.24 Million
Q3 2023 Nov 14, 2023	SELL	$11.84 - $18.65 $36,704 - $57,814	-3,100 Reduced 25.2%	9,200 $140,000
Q2 2023 Aug 14, 2023	SELL	$7.65 - $13.95 $70,380 - $128,340	-9,200 Reduced 42.79%	12,300 $158,000
Q1 2023 May 15, 2023	SELL	$7.08 - $12.62 $19,116 - $34,074	-2,700 Reduced 11.16%	21,500 $177,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $37,760 - $548,700	-59,000 Reduced 70.91%	24,200 $223,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $2.05 $52,416 - $170,559	83,200 New	83,200 $54,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $87.3M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.